Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
Conditions: Vaccine Reaction; Vaccine Adverse Reaction Interventions: Biological: Hepatitis B vaccine lot 1; Biological: Hepatitis B vaccine lot 2; Biological: Hepatitis B vaccine lot 3; Biological: Hepatitis B vaccine (registered) Sponsors: PT Bio Farma; RS Umum Pusat Sanglah, Denpasar Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials